Assessment of Risks, Challenges and Opportunities in Conducting Foreign Bioequivalence Studies

Nageshwar R Thudi Ph.D. Senior Director, Global Gx Clinical R&D- PD/CE Studies

Generic and Biosimilar Medicines Conference- November 6, 2019

Disclaimer:

- The views and opinions expressed in this presentation are those of the individual presenter and do not necessarily reflect the opinions of Teva

Focus of the Presentation

- In this presentation I am mainly focusing in conducting foreign PD/CE Bioequivalence studies with Sponsor perspective

Trial Level Roles and Responsibilities of Sponsor



Sponsor Team Customers



Per study on Average 300 to 500 people work is directly or indirectly

Deciding Factors (Go/No Go)

01 Therapeutic Area / Patient factors/ Opportunities

02 Regulatory Requirements

03 Logistics

04 Budget and timelines

05 Protocol specific concerns

06 Quality and compliance

Therapeutic Area / Patient factors

01 Local Therapeutic Area (TA) experience

02 Some study designs have no choice like Travelers Diarrhea

03 Exercise Caution for some TAs or diseases like Toe Nail fungus

04 Glaucoma (light and dark colored Iris FDA requirement)

05 Seasons/ Time zones (otitis media/ otitis externa)

Therapeutic Area / Patient factors/ Opportunities

01 Geographical locations (not all countries are suitable for all TAs)

02 Disease Prevalence in particular country (conduct the feasibility)

03 Skin Blanching studies and responder rate

04 FDA expectations vs. local regulatory requirements (like Age restrictions)

05 IRB approvals/rejections (like patient benefit assessment)

06 Patient availability vs. site experience

Regulatory Requirements

01 CMC (IMPD, IB) documentation (Multiple countries!!)

02 Preclinical data, other requirement if the product not approved in local country

03 Timelines for regulatory CTA approvals

04 Translations and Insurance requirements

05 QP Release, GMP status and other IP related requirements

06 Local (safety/data/privacy) Reporting requirements

Logistics

01 Additional facilities Drug Depots/ central lab/ Retention etc.

02 Permits needed for IP/ ancillary supplies/equipment Imports

03 Sponsor/ CRO/ QA travel

04 Time Zone differences and Holidays

05 Language translations

06 Duties/Taxes/shipment costs

Investigator Sites

01 Finding sites who can meet protocol requirements

02 GCP Knowledge

03 Adequate facilities and trained staff

04 Language

05 Patient Database/ Screen failure Rate

06 Institutions CTAs/ IRB etc.

Patients (Things to Train/Monitor)

01 Patient compliance (IP application, study visits)

02 Documentation (Diary entry and AE reporting)

03 Language (Literacy, Translators, ICF, Diaries)

04 Disease status and con meds reporting

05 Predicting drop out rate

06 Age/ Gender/ Social recruitment challenges

Final Thoughts

01 Advantage (Budget) vs. previously explained complexities

02 Work Load i.e. Sometimes one project will become 3 projects work load

03 Product Approval timelines (investigator inspections etc.)

04 Quality and compliance

05 Study vs. Product approval timelines (CTA approval, recruitment and inspections)

06 Apply science with logic

For Successful Study

- Plan for Investigator meeting (set the expectations right)
- Make sure site has all the facilities (IP storage, Internet connection etc.)
- Provide all the tools and supplies to the site
- Conduct SIVs (may be repeat of IM)
- 100% Monitoring (may be more)
- QA oversight
- Central Monitoring (use EDC, IWRS etc.) for trends

For Successful Study

- Enrollment projection estimation (may be only 30% what site promises)
- Have back up sites ready
- Frequent data review/trend meetings
- Make sure sites entering the data ASAP
- Proper review of I/E criteria (prohibited medications and other restrictions)
- Review the data on time and raise the queries on time
- Investigate and Report quality/compliance issues properly

Abbreviations

Abbreviation	Full Phrase
PD/CE studies	Pharmacodynamic / Clinical End Point Studies
IRB	Institutional Review Board
IP	Investigational Product
CRO	Clinical Research Organization
PM	Project Manager
RA	Regulatory Affairs
EDC	Electronic Data Capture
IWRS	Interactive Web Response System
CRAs	Clinical Research Associates
IM	Investigator Meeting
IMPD	Investigational Medicinal Product Dossier
IB	Investigator Brochure
CTA	Clinical Trial Application (agreement)
GCP	Good Clinical Practice
AE	Adverse Event
ICF	Informed Consent Form
SIVs	Site Intiation Visits
I/E Criteria	Inclusion/Exclusion Criteria

Acknowledgements

- A BIG THANK YOU to

- Charlie DiLiberti, President, Montclair Bioequivalence Services, LLC
- Gregg Derosa, Senior Vice President, Teva Pharmaceuticals
- AAM Team

Thank you.